AlphaRx Concludes GAI-122 Formulation Development Intended For The Prevention o...(memory disturbances produced by cerebral...),Health

Date:8/27/2009

memory disturbances produced by cerebral embolization, cerebral ischemia or lesions in the basal forebrain, the area of origin of the acetylcholine neuron system projecting into the cerebral cortex, hippocampus and amygdala. In clinical tests, an oral form of GAI-122 has been shown to be effective in preventing psychological deficits, such as a decline in memory retention and orientation.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

'/>"/>

SOURCE AlphaRx Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. AlphaRx To Present at 47th Annual ICAAC
2. AlphaRx Announces Debt Conversion
3. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
4. AlphaRx CEO Accumulates More Company Shares
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx Provides Corporate and Development Update
7. AlphaRx Signs Cooperative Research and Development Agreement with US Army
8. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
9. AlphaRx Shareholder Update
10. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
11. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease